R Squared Ltd Invests $34,000 in PetMed Express, Inc. $PETS

R Squared Ltd bought a new stake in PetMed Express, Inc. (NASDAQ:PETS) during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm bought 10,157 shares of the company’s stock, valued at approximately $34,000.

Other hedge funds have also recently added to or reduced their stakes in the company. Goldman Sachs Group Inc. raised its holdings in PetMed Express by 59.3% in the first quarter. Goldman Sachs Group Inc. now owns 33,209 shares of the company’s stock valued at $139,000 after acquiring an additional 12,360 shares in the last quarter. Caption Management LLC acquired a new stake in PetMed Express in the first quarter valued at approximately $242,000. American Century Companies Inc. raised its holdings in PetMed Express by 80.1% in the first quarter. American Century Companies Inc. now owns 60,629 shares of the company’s stock valued at $254,000 after acquiring an additional 26,967 shares in the last quarter. Finally, Universal Beteiligungs und Servicegesellschaft mbH acquired a new stake in PetMed Express in the first quarter valued at approximately $295,000. Institutional investors and hedge funds own 73.33% of the company’s stock.

Insider Activity

In other news, major shareholder Silvercape Investments Ltd purchased 118,200 shares of the business’s stock in a transaction dated Friday, August 1st. The stock was acquired at an average price of $3.21 per share, with a total value of $379,422.00. Following the purchase, the insider directly owned 2,478,696 shares of the company’s stock, valued at $7,956,614.16. This represents a 5.01% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 1.10% of the stock is owned by company insiders.

Analysts Set New Price Targets

A number of research firms have weighed in on PETS. Wall Street Zen cut shares of PetMed Express from a “hold” rating to a “sell” rating in a report on Saturday, October 18th. Zacks Research raised shares of PetMed Express from a “strong sell” rating to a “hold” rating in a report on Monday, September 29th. Finally, Weiss Ratings reissued a “sell (d)” rating on shares of PetMed Express in a report on Saturday. One research analyst has rated the stock with a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Sell” and a consensus price target of $3.20.

PetMed Express Price Performance

NASDAQ:PETS opened at $2.74 on Monday. PetMed Express, Inc. has a 1-year low of $2.42 and a 1-year high of $6.85. The firm has a market cap of $57.59 million, a price-to-earnings ratio of -9.13 and a beta of 0.73. The firm’s fifty day moving average price is $2.78 and its 200 day moving average price is $3.22.

PetMed Express (NASDAQ:PETS) last released its earnings results on Tuesday, October 14th. The company reported ($0.56) EPS for the quarter, missing the consensus estimate of $0.04 by ($0.60). The firm had revenue of $46.47 million during the quarter. PetMed Express had a negative return on equity of 6.76% and a negative net margin of 2.76%. As a group, analysts expect that PetMed Express, Inc. will post 0.19 earnings per share for the current fiscal year.

PetMed Express Profile

PetMed Express, Inc, together with its subsidiaries, operates as a pet pharmacy in the United States. The company markets prescription and non-prescription pet medications, health products, and other supplies for dogs, cats, and horses. It offers non-prescription medications and supplies, such as flea and tick control products, bone and joint care products, vitamins, treats, nutritional supplements, hygiene products, and household pet supplies; and prescription medications, including heartworm preventatives, flea and tick preventatives, arthritis, dermatitis, thyroid, diabetes, pain medications, heart/blood pressure, and other specialty medications, as well as generic substitutes.